BioSpace News Archive

CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced changes to its Supervisory Board.

Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on March 11, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 31 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and patients involved in ongoing clinical studies of Arrowhead’s investigational medicines

NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its audited consolidated results for the fiscal year ending December 31, 2019:

On March 16, FDA updated its guidance on COVID-19 testing to allow clinical labs to create and perform COVID-19 tests without pursuing FDA emergency use authorization (EUA)

Starting Wednesday, BayCare patients who have been instructed by their doctor to be tested for COVID-19 will be able to provide a specimen for testing without leaving their cars.

The U.S. Food and Drug Administration took steps to help prevent disruptions in the food supply-chain by issuing a temporary policy for FDA Food Safety Modernization Act supplier verification onsite audit requirements during the coronavirus public health emergency.

NKMax America announced that Dr. Paul Song, Vice Chairman and Chief Medical Officer of NKMax America, has been selected to present at the upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23-24, 2020.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19.

Agilent Technologies, Inc. (NYSE: A) today announced plans to adjourn its annual meeting of stockholders, originally scheduled to be held March 18, 2020, due to public health considerations relating to the outbreak of COVID-19 and the need to comply with federal, state and local restrictions on gatherings and movement.